NCT07050134 - A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

May 11, 2026

Study Completion Date

July 5, 2026

Conditions

HypertriglyceridemiaCarotid Atherosclerotic Plaques

Interventions

DRUG

DR10624 Injection；

"The experimental group(Trial Drug)~* Name: DR10624 Injection (referred to as DR10624)~* Specification: 60mg (1mL)/vial~* Active Ingredient: DR10624~* Route of Administration: Subcutaneous injection~* Packaging: Vial~* Expiry Date: See the drug label~* Storage Conditions: 2\~8℃, protected from light~* Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd.~* Supplier: Zhejiang Daor Biotechnology Co., Ltd."

DRUG

DR10624 Injection Placebo (referred to as placebo)

(The control group)Placebo: Name: DR10624 Injection Placebo (referred to as placebo) Specification: 0mg (1mL)/vial (no active ingredient) Main Component: Normal saline Route of Administration: Subcutaneous injection Packaging: Vial Expiry Date: See the drug label Storage Conditions: 2\~8℃, protected from light Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd. Supplier: Zhejiang Daor Biotechnology Co., Ltd.

Trial Locations (1)

Unknown

Zhongshan Hospital Affiliated with Fudan University, Shanghai

All Listed Sponsors

collaborator

Zhejiang Doer Biologics Co., Ltd.

INDUSTRY

lead

Junbo Ge

OTHER